The Experts below are selected from a list of 225 Experts worldwide ranked by ideXlab platform
John H Riley - One of the best experts on this subject based on the ideXlab platform.
-
Effect of umeclidinium/vilanterol (UMEC/VI) on inspiratory Capacity/Total Lung Capacity ratio in hyperinflated COPD patients
European Respiratory Journal, 2015Co-Authors: Sally Singh, Francois Maltais, Lee Tombs, Alison Church, Ahmar Iqbal, John H RileyAbstract:Background: Ratio of inspiratory Capacity (IC) to Total Lung Capacity (TLC) is an independent predictor of mortality in patients with COPD; Objective: To determine if UMEC/VI, UMEC or VI could improve the IC/TLC ratio vs placebo (PBO) in hyperinflated patients in a post hoc analysis. Methods: We investigated the effect of UMEC/VI (62.5/25mcg), VI (25mcg) and UMEC (62.5mcg) vs PBO on hyperinflation (IC/TLC ratio), using pooled data from two 3-month cross-over exercise studies enrolling 358 hyperinflated (Functional Residual Capacity >120%) patients with COPD. Results: Statistically significant improvements in trough IC/TLC ratios for all treatments vs PBO were shown at 12 weeks in the hyperinflated COPD population. Adverse event rates were similar across treatment groups. Conclusion: UMEC/VI showed a greater improvement in IC/TLC ratio than UMEC or VI, suggesting that in hyperinflated patients with COPD a dual bronchodilator is more effective than either component. Longer-term clinical trials are required to determine if these improvements in hyperinflation affect COPD mortality. Funding: NCT/GSK number: 01328444/114417, 01323660/114418.
-
effect of umeclidinium vilanterol umec vi on inspiratory Capacity Total Lung Capacity ratio in hyperinflated copd patients
European Respiratory Journal, 2015Co-Authors: Sally Singh, Francois Maltais, Lee Tombs, Alison Church, Ahmar Iqbal, John H RileyAbstract:Background: Ratio of inspiratory Capacity (IC) to Total Lung Capacity (TLC) is an independent predictor of mortality in patients with COPD; Objective: To determine if UMEC/VI, UMEC or VI could improve the IC/TLC ratio vs placebo (PBO) in hyperinflated patients in a post hoc analysis. Methods: We investigated the effect of UMEC/VI (62.5/25mcg), VI (25mcg) and UMEC (62.5mcg) vs PBO on hyperinflation (IC/TLC ratio), using pooled data from two 3-month cross-over exercise studies enrolling 358 hyperinflated (Functional Residual Capacity >120%) patients with COPD. Results: Statistically significant improvements in trough IC/TLC ratios for all treatments vs PBO were shown at 12 weeks in the hyperinflated COPD population. Adverse event rates were similar across treatment groups. Conclusion: UMEC/VI showed a greater improvement in IC/TLC ratio than UMEC or VI, suggesting that in hyperinflated patients with COPD a dual bronchodilator is more effective than either component. Longer-term clinical trials are required to determine if these improvements in hyperinflation affect COPD mortality. Funding: NCT/GSK number: 01328444/114417, 01323660/114418.
Sally Singh - One of the best experts on this subject based on the ideXlab platform.
-
Effect of umeclidinium/vilanterol (UMEC/VI) on inspiratory Capacity/Total Lung Capacity ratio in hyperinflated COPD patients
European Respiratory Journal, 2015Co-Authors: Sally Singh, Francois Maltais, Lee Tombs, Alison Church, Ahmar Iqbal, John H RileyAbstract:Background: Ratio of inspiratory Capacity (IC) to Total Lung Capacity (TLC) is an independent predictor of mortality in patients with COPD; Objective: To determine if UMEC/VI, UMEC or VI could improve the IC/TLC ratio vs placebo (PBO) in hyperinflated patients in a post hoc analysis. Methods: We investigated the effect of UMEC/VI (62.5/25mcg), VI (25mcg) and UMEC (62.5mcg) vs PBO on hyperinflation (IC/TLC ratio), using pooled data from two 3-month cross-over exercise studies enrolling 358 hyperinflated (Functional Residual Capacity >120%) patients with COPD. Results: Statistically significant improvements in trough IC/TLC ratios for all treatments vs PBO were shown at 12 weeks in the hyperinflated COPD population. Adverse event rates were similar across treatment groups. Conclusion: UMEC/VI showed a greater improvement in IC/TLC ratio than UMEC or VI, suggesting that in hyperinflated patients with COPD a dual bronchodilator is more effective than either component. Longer-term clinical trials are required to determine if these improvements in hyperinflation affect COPD mortality. Funding: NCT/GSK number: 01328444/114417, 01323660/114418.
-
effect of umeclidinium vilanterol umec vi on inspiratory Capacity Total Lung Capacity ratio in hyperinflated copd patients
European Respiratory Journal, 2015Co-Authors: Sally Singh, Francois Maltais, Lee Tombs, Alison Church, Ahmar Iqbal, John H RileyAbstract:Background: Ratio of inspiratory Capacity (IC) to Total Lung Capacity (TLC) is an independent predictor of mortality in patients with COPD; Objective: To determine if UMEC/VI, UMEC or VI could improve the IC/TLC ratio vs placebo (PBO) in hyperinflated patients in a post hoc analysis. Methods: We investigated the effect of UMEC/VI (62.5/25mcg), VI (25mcg) and UMEC (62.5mcg) vs PBO on hyperinflation (IC/TLC ratio), using pooled data from two 3-month cross-over exercise studies enrolling 358 hyperinflated (Functional Residual Capacity >120%) patients with COPD. Results: Statistically significant improvements in trough IC/TLC ratios for all treatments vs PBO were shown at 12 weeks in the hyperinflated COPD population. Adverse event rates were similar across treatment groups. Conclusion: UMEC/VI showed a greater improvement in IC/TLC ratio than UMEC or VI, suggesting that in hyperinflated patients with COPD a dual bronchodilator is more effective than either component. Longer-term clinical trials are required to determine if these improvements in hyperinflation affect COPD mortality. Funding: NCT/GSK number: 01328444/114417, 01323660/114418.
Ahmar Iqbal - One of the best experts on this subject based on the ideXlab platform.
-
Effect of umeclidinium/vilanterol (UMEC/VI) on inspiratory Capacity/Total Lung Capacity ratio in hyperinflated COPD patients
European Respiratory Journal, 2015Co-Authors: Sally Singh, Francois Maltais, Lee Tombs, Alison Church, Ahmar Iqbal, John H RileyAbstract:Background: Ratio of inspiratory Capacity (IC) to Total Lung Capacity (TLC) is an independent predictor of mortality in patients with COPD; Objective: To determine if UMEC/VI, UMEC or VI could improve the IC/TLC ratio vs placebo (PBO) in hyperinflated patients in a post hoc analysis. Methods: We investigated the effect of UMEC/VI (62.5/25mcg), VI (25mcg) and UMEC (62.5mcg) vs PBO on hyperinflation (IC/TLC ratio), using pooled data from two 3-month cross-over exercise studies enrolling 358 hyperinflated (Functional Residual Capacity >120%) patients with COPD. Results: Statistically significant improvements in trough IC/TLC ratios for all treatments vs PBO were shown at 12 weeks in the hyperinflated COPD population. Adverse event rates were similar across treatment groups. Conclusion: UMEC/VI showed a greater improvement in IC/TLC ratio than UMEC or VI, suggesting that in hyperinflated patients with COPD a dual bronchodilator is more effective than either component. Longer-term clinical trials are required to determine if these improvements in hyperinflation affect COPD mortality. Funding: NCT/GSK number: 01328444/114417, 01323660/114418.
-
effect of umeclidinium vilanterol umec vi on inspiratory Capacity Total Lung Capacity ratio in hyperinflated copd patients
European Respiratory Journal, 2015Co-Authors: Sally Singh, Francois Maltais, Lee Tombs, Alison Church, Ahmar Iqbal, John H RileyAbstract:Background: Ratio of inspiratory Capacity (IC) to Total Lung Capacity (TLC) is an independent predictor of mortality in patients with COPD; Objective: To determine if UMEC/VI, UMEC or VI could improve the IC/TLC ratio vs placebo (PBO) in hyperinflated patients in a post hoc analysis. Methods: We investigated the effect of UMEC/VI (62.5/25mcg), VI (25mcg) and UMEC (62.5mcg) vs PBO on hyperinflation (IC/TLC ratio), using pooled data from two 3-month cross-over exercise studies enrolling 358 hyperinflated (Functional Residual Capacity >120%) patients with COPD. Results: Statistically significant improvements in trough IC/TLC ratios for all treatments vs PBO were shown at 12 weeks in the hyperinflated COPD population. Adverse event rates were similar across treatment groups. Conclusion: UMEC/VI showed a greater improvement in IC/TLC ratio than UMEC or VI, suggesting that in hyperinflated patients with COPD a dual bronchodilator is more effective than either component. Longer-term clinical trials are required to determine if these improvements in hyperinflation affect COPD mortality. Funding: NCT/GSK number: 01328444/114417, 01323660/114418.
Alison Church - One of the best experts on this subject based on the ideXlab platform.
-
Effect of umeclidinium/vilanterol (UMEC/VI) on inspiratory Capacity/Total Lung Capacity ratio in hyperinflated COPD patients
European Respiratory Journal, 2015Co-Authors: Sally Singh, Francois Maltais, Lee Tombs, Alison Church, Ahmar Iqbal, John H RileyAbstract:Background: Ratio of inspiratory Capacity (IC) to Total Lung Capacity (TLC) is an independent predictor of mortality in patients with COPD; Objective: To determine if UMEC/VI, UMEC or VI could improve the IC/TLC ratio vs placebo (PBO) in hyperinflated patients in a post hoc analysis. Methods: We investigated the effect of UMEC/VI (62.5/25mcg), VI (25mcg) and UMEC (62.5mcg) vs PBO on hyperinflation (IC/TLC ratio), using pooled data from two 3-month cross-over exercise studies enrolling 358 hyperinflated (Functional Residual Capacity >120%) patients with COPD. Results: Statistically significant improvements in trough IC/TLC ratios for all treatments vs PBO were shown at 12 weeks in the hyperinflated COPD population. Adverse event rates were similar across treatment groups. Conclusion: UMEC/VI showed a greater improvement in IC/TLC ratio than UMEC or VI, suggesting that in hyperinflated patients with COPD a dual bronchodilator is more effective than either component. Longer-term clinical trials are required to determine if these improvements in hyperinflation affect COPD mortality. Funding: NCT/GSK number: 01328444/114417, 01323660/114418.
-
effect of umeclidinium vilanterol umec vi on inspiratory Capacity Total Lung Capacity ratio in hyperinflated copd patients
European Respiratory Journal, 2015Co-Authors: Sally Singh, Francois Maltais, Lee Tombs, Alison Church, Ahmar Iqbal, John H RileyAbstract:Background: Ratio of inspiratory Capacity (IC) to Total Lung Capacity (TLC) is an independent predictor of mortality in patients with COPD; Objective: To determine if UMEC/VI, UMEC or VI could improve the IC/TLC ratio vs placebo (PBO) in hyperinflated patients in a post hoc analysis. Methods: We investigated the effect of UMEC/VI (62.5/25mcg), VI (25mcg) and UMEC (62.5mcg) vs PBO on hyperinflation (IC/TLC ratio), using pooled data from two 3-month cross-over exercise studies enrolling 358 hyperinflated (Functional Residual Capacity >120%) patients with COPD. Results: Statistically significant improvements in trough IC/TLC ratios for all treatments vs PBO were shown at 12 weeks in the hyperinflated COPD population. Adverse event rates were similar across treatment groups. Conclusion: UMEC/VI showed a greater improvement in IC/TLC ratio than UMEC or VI, suggesting that in hyperinflated patients with COPD a dual bronchodilator is more effective than either component. Longer-term clinical trials are required to determine if these improvements in hyperinflation affect COPD mortality. Funding: NCT/GSK number: 01328444/114417, 01323660/114418.
Lee Tombs - One of the best experts on this subject based on the ideXlab platform.
-
Effect of umeclidinium/vilanterol (UMEC/VI) on inspiratory Capacity/Total Lung Capacity ratio in hyperinflated COPD patients
European Respiratory Journal, 2015Co-Authors: Sally Singh, Francois Maltais, Lee Tombs, Alison Church, Ahmar Iqbal, John H RileyAbstract:Background: Ratio of inspiratory Capacity (IC) to Total Lung Capacity (TLC) is an independent predictor of mortality in patients with COPD; Objective: To determine if UMEC/VI, UMEC or VI could improve the IC/TLC ratio vs placebo (PBO) in hyperinflated patients in a post hoc analysis. Methods: We investigated the effect of UMEC/VI (62.5/25mcg), VI (25mcg) and UMEC (62.5mcg) vs PBO on hyperinflation (IC/TLC ratio), using pooled data from two 3-month cross-over exercise studies enrolling 358 hyperinflated (Functional Residual Capacity >120%) patients with COPD. Results: Statistically significant improvements in trough IC/TLC ratios for all treatments vs PBO were shown at 12 weeks in the hyperinflated COPD population. Adverse event rates were similar across treatment groups. Conclusion: UMEC/VI showed a greater improvement in IC/TLC ratio than UMEC or VI, suggesting that in hyperinflated patients with COPD a dual bronchodilator is more effective than either component. Longer-term clinical trials are required to determine if these improvements in hyperinflation affect COPD mortality. Funding: NCT/GSK number: 01328444/114417, 01323660/114418.
-
effect of umeclidinium vilanterol umec vi on inspiratory Capacity Total Lung Capacity ratio in hyperinflated copd patients
European Respiratory Journal, 2015Co-Authors: Sally Singh, Francois Maltais, Lee Tombs, Alison Church, Ahmar Iqbal, John H RileyAbstract:Background: Ratio of inspiratory Capacity (IC) to Total Lung Capacity (TLC) is an independent predictor of mortality in patients with COPD; Objective: To determine if UMEC/VI, UMEC or VI could improve the IC/TLC ratio vs placebo (PBO) in hyperinflated patients in a post hoc analysis. Methods: We investigated the effect of UMEC/VI (62.5/25mcg), VI (25mcg) and UMEC (62.5mcg) vs PBO on hyperinflation (IC/TLC ratio), using pooled data from two 3-month cross-over exercise studies enrolling 358 hyperinflated (Functional Residual Capacity >120%) patients with COPD. Results: Statistically significant improvements in trough IC/TLC ratios for all treatments vs PBO were shown at 12 weeks in the hyperinflated COPD population. Adverse event rates were similar across treatment groups. Conclusion: UMEC/VI showed a greater improvement in IC/TLC ratio than UMEC or VI, suggesting that in hyperinflated patients with COPD a dual bronchodilator is more effective than either component. Longer-term clinical trials are required to determine if these improvements in hyperinflation affect COPD mortality. Funding: NCT/GSK number: 01328444/114417, 01323660/114418.
